1. Therapeutic monoclonal antibodies approved by FDA in 2017;Cai;MOJ Immunol,2018
2. Avoiding antibody aggregation during processing: establishing hold times;Joshi;Biotechnol. J.,2014
3. Improved in vivo stability and tumor targeting of bismuth-labeled antibody;Ruegg;Canc. Res.,1990
4. Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates;Gébleux;Mol. Canc. Therapeut.,2015
5. The importance of handling high-value biologicals: physico-chemical instability and immunogenicity of monoclonal antibodies;Laptoš;Exp Ther Med,2018